ライブラリ登録: Guest
Critical Reviews™ in Eukaryotic Gene Expression

年間 6 号発行

ISSN 印刷: 1045-4403

ISSN オンライン: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Inhibition of Hepatitis B Virus with the Help of CRISPR/Cas9 Technology

巻 30, 発行 3, 2020, pp. 273-278
DOI: 10.1615/CritRevEukaryotGeneExpr.2020028453
Get accessGet access

要約

Hepatitis B infection caused by hepatitis B virus (HBV) is a serious health issue worldwide. Existing therapeutic strategies hardly eradicate HBV infections, and they fail to attain complete cure. Advanced treatment strategies are urgently needed to successfully terminate further spread of HBV infection and eliminate hidden reservoirs of virus. Recently, a novel RNA-guided gene editing tool, known as the clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9 (CRISPR/Cas9) system, has been established. It facilitates site-specific mutagenesis and reveals a new way to develop applicable techniques for disease treatment, such as extermination of infectious agents like HBV This study highlights the current developments in CRISPR/Cas9 technology and its importance for target-specific inhibition of HBV genome. Benefits, challenges, feasible solutions, and proposed guidelines for forthcoming study in CRISPR/Cas9 are described to highlight the possible cures of and treatments for chronic HBV infection.

参考
  1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer world-wide. J Hepatol. 2006;45(4):529-38.

  2. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler MH, Huser N, Durantel D, Liang TJ, Munk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343(6176):1221-8.

  3. Isorce N, Lucifora J, Zoulim F, Durantel D. Immune-modulators to combat hepatitis B virus infection: From IFN-a to novel investigational immunotherapeutic strategies. Antiviral Res. 2015;122:69-81.

  4. Niaz M, Qadir M, Niaz M. Tumor markers for early detection of cancer. Pharmacologyonline. 2010;3:628-33.

  5. Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81.

  6. Kennedy EM, Bassit LC, Mueller H, Kornepati AV, Bogerd HP, Nie T, Chatterjee P, Javanbakht H, Schinazi RF, Cullen BR. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 2015;476:196-205.

  7. Li H, Sheng C, Wang S, Yang L, Liang Y, Huang Y, Liu H, Li P, Yang C, Yang X, Jia L, Xie J, Wang L, Hao R, Du X, Xu D, Zhou J, Li M, Sun Y, Tong Y, Li Q, Song H. Removal of integrated hepatitis B virus DNA using CRIS-PR-Cas9. Front Cell Infect Microbiol. 2017;7:91.

  8. Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JJ, Joung JK. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013;31(3):227-9.

  9. Gebbing M, Bergmann T, Schulz E, Ehrhardt A. Gene therapeutic approaches to inhibit hepatitis B virus replica-tion. World J Hepatol. 2015;7(2):150-64.

  10. Ayoub W, Keeffe E. Review article: Current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34(10):1145-58.

  11. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14):1486-500.

  12. Peng C, Lu M, Yang D. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV. Virol Sin. 2015;30(5):317-25.

  13. Lin G, Zhang K, Li J. Application of CRISPR/Cas9 technology to HBV. Int J Mol Sci. 2015;16(11):26077-86.

  14. Liu X, Hao R, Chen S, Guo D, Chen Y. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. J Gen Virol. 2015;96(8):2252-61.

  15. Qadir M. Advances in treatment of lungs cancer. Independ Rev. 2011;103:176-80.

  16. Mei Y, Wang Y, Chen H, Sun ZS, Ju X-D. Recent progress in CRISPR/Cas9 technology. J Genet Genomics. 2016;43(2):63-75.

  17. Moyo B, Bloom K, Scott T, Ely A, Arbuthnot P. Advances with using CRISPR/Cas-mediated gene editing to treat in-fections with hepatitis B virus and hepatitis C virus. Virus Res. 2017;244:311-20.

  18. Zhen S, Hua L, Liu Y, Gao L, Fu J, Wan D, Dong L, Song H, Gao X. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther. 2015;22(5):404-12.

  19. Ramanan V, Shlomai A, Cox DBT, Schwartz RE, Michailidis E, Bhatta A, Scott DA, Zhang F, Rice CM, Bhatia SN. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep. 2015;5:10833.

  20. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003): 1546-55.

  21. Seeger C, Sohn JA. Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids. 2014;3(12):e216.

  22. Karimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann JH, Grundhoff A, Luth S, Buchholz F, Zur Wiesch JS, Hauber J. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep. 2015;5(1):1-6.

  23. Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, Wang L, Hodgkins A, Iyer V, Huang X, Skarnes WC. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014;11(4):399-402.

  24. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479:672-86.

  25. Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA, Liang C. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology. 2015;12(1):22.

  26. Hai H, Tamori A, Kawada N. Role of hepatitis B virus DNA integration in human hepatocarcinogenesis. World J Gastroenterol. 2014;20(20):6236-43.

  27. Kennedy EM, Cullen BR. Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. Virology. 2015;479:213-20.

  28. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32(6):551-3.

  29. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84-7.

  30. Xu T, Li Y, Van Nostrand JD, He Z, Zhou J. Cas9-based tools for targeted genome editing and transcriptional control. Appl Environ Microbiol. 2014;80(5):1544-52.

  31. Yang H-C, Kao J-H. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: Molecular mechanisms and clinical significance. Emerg Microbes Infect. 2014;3(9):e64.

  32. Komatsu H. Hepatitis B virus: Where do we stand and what is the next step for eradication? World J Gastroenterol. 2014;20(27):8998-9016.

  33. Kennedy EM, Kornepati AV, Mefferd AL, Marshall JB, Tsai K, Bogerd HP, Cullen BR. Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic. Methods. 2015;91:82-6.

  34. Wyman C, Kanaar R. DNA double-strand break repair: All's well that ends well. Annu Rev Genet. 2006; 40:363-83.

  35. Yan H, Peng B, He W, Zhong G, Qi Y, Ren B, Gao Z, Jing Z, Song M, Xu G, Sui J, Li W. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol. 2013;87(14):7977-91.

  36. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell. 2013;154(6):1370-9.

によって引用された
  1. Teng Man, Yao Yongxiu, Nair Venugopal, Luo Jun, Latest Advances of Virology Research Using CRISPR/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development, Viruses, 13, 5, 2021. Crossref

  2. Qadir M.I., Meet Our Editorial Board Member, Recent Patents on Biotechnology, 15, 1, 2021. Crossref

  3. Wang Yaya, Huang Chun, Zhao Weiqin, Recent advances of the biological and biomedical applications of CRISPR/Cas systems, Molecular Biology Reports, 49, 7, 2022. Crossref

1584 記事の閲覧数 22 記事のダウンロード 記事の統計
1584 記事の閲覧数 22 記事のダウンロード 3 Crossref 引用数 Google
Scholar
引用数

類似内容の記事:

COVID-19 Threat to the World: Current and Possible Diagnostic/Treatment Strategies Critical Reviews™ in Biomedical Engineering, Vol.49, 2021, issue 1
Saima Wajid, Mohd Mughees, Himanshu Chugh, Samar Husain Naqvi
Methylation-Based Biomarkers for Early Detection of Urological Cancer Critical Reviews™ in Oncogenesis, Vol.13, 2007, issue 4
Carmen Jeronimo, Rui Manuel Ferreira Henrique, Vera L. Costa
Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer Journal of Environmental Pathology, Toxicology and Oncology, Vol.42, 2023, issue 4
Md. Abubakar, Ahsas Goyal, V. G. M. Naidu, Gaurav Gupta, Vetriselvan Subramaniyan, Waleed Hassan Almalki, Ch. Veera Bhadrawamy, S. Roshan, Fahim Anwar Rizwi, Sushama Rawat, Eswara Rao Puppala, B. Tazneem
COVID-19 Infection: Targeting Possibilities for Treatment Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.38, 2021, issue 3
Indu Lata Kanwar, Rahul Tiwari, Avijit Kumar Bakshi, Monika Vishwakarma, Vishal Gour, Ravishankar Yadav, Arkadeep Sarkar, Vandana Soni, Vikas Pandey, Sakshi Soni, Tanweer Haider
Human Immunodeficiency Virus Type 1 Pharmacogenomics in Clinical Practice: Relevance of HIV-1 Drug Resistance Testing (Part 1) Journal of Environmental Pathology, Toxicology and Oncology, Vol.22, 2003, issue 3
Nancy G. Klimas, Margaret Marchette, Charles Mitchell, Eduardo Meneses Sierra, Alejandro Isava, Dushyantha Jayaweera, Enriqueta Nunez, J. Brian Page, Gwendolyn Scott, Roberto Patarca, Nelson J. Rodriguez, Mary Ann Fletcher, Delia Rivera, Michael Kolber, Mirtha M. Sanabia, Rafael Campo, Cindy W. Mask, Jose Moreno, Michael Alter, Ricardo Vallejo, Catherine Boulanger

近刊の記事

PRMT6 promotes the immune evasion of gastric cancer via upregulating ANXA1 Liang Xu, Fenger Zhang, Binqi Yu, Shengnan Jia, Sunfu Fan PURPL promotes M2 macrophage polarization in lung cancer via regulating RBM4/xCT signaling Jipeng Guo, Chongwen Gong, Hao Wang SIAH1 promotes the pyroptosis of cardiomyocytes in diabetic cardiomyopathy via regulating IκB-α/NF-κB signaling Jinbin Wu, Yaoming Yan SLC7A2-mediated lysine catabolism inhibits immunosuppression in triple negative breast cancer Yuanyuan Sun, Yaqing Li, Chengying Jiang, Chenying Liu, Yuanming Song SIAH2-mediated degradation of ACSL4 inhibits the anti-tumor activity of CD8+ T cells in hepatocellular carcinoma Fangzheng Shu, Yuhua Shi, Xiangxiang Shan, Wenzhang Zha, Rengen Fan, Wanjiang Xue RBM15-mediated N6-methyl adenosine (m6A) modification of EZH2 drives the epithelial-mesenchymal transition of cervical cancer Ruixue Wang, Wenhua Tan Evidence-Based Storytelling and A Strategic Roadmap to Promote Cancer Prevention Via Adolescent HPV Vaccination in Northern New England Matthew Dugan, Gary Stein, Jan Carney, Sheila Clifford-Bova KDM4A-AS1 promotes cell proliferation, migration and invasion via the miR-4306/STX6 axis in hepatocellular carcinoma Wei Cao, Yuhan Ren, Ying Liu, Guoshu Cao, Zhen Chen, Fan Wang HDAC1-mediated downregulation of NEU1 exacerbates the aggressiveness of cervical cancer Nanzi Xie, Sisi Mei, Changlan Dai, Wei Chen Effect of miR-26b-5p on progression of acute myeloid leukemia by regulating USP48-mediated Wnt/β-catenin pathway Yu Xie, Lin Tan, Kun Wu, Deyun Li, Chengping Li
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain